There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Axsome Therapeutics (AXSM), Exelixis (EXEL) and Lyra Therapeutics (LYRA) with bullish sentiments.
Axsome Therapeutics (AXSM)
William Blair analyst Myles Minter reiterated a Buy rating on Axsome Therapeutics on August 6. The company’s shares closed last Friday at $78.07.
According to TipRanks.com, Minter is a 4-star analyst with an average return of 39.1% and a 60.0% success rate. Minter covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals, Minerva Neurosciences, and Karuna Therapeutics.
Currently, the analyst consensus on Axsome Therapeutics is a Moderate Buy with an average price target of $210.00, implying a 168.3% upside from current levels. In a report issued on July 28, H.C. Wainwright also reiterated a Buy rating on the stock with a $210.00 price target.
See today’s analyst top recommended stocks >>
Exelixis (EXEL)
In a report issued on August 5, Andy Hsieh from William Blair maintained a Buy rating on Exelixis. The company’s shares closed last Friday at $22.36.
According to TipRanks.com, Hsieh is a 4-star analyst with an average return of 17.4% and a 57.6% success rate. Hsieh covers the Healthcare sector, focusing on stocks such as Actinium Pharmaceuticals, Viking Therapeutics, and Seattle Genetics.
Currently, the analyst consensus on Exelixis is a Strong Buy with an average price target of $31.17, which is a 34.6% upside from current levels. In a report issued on August 7, Oppenheimer also maintained a Buy rating on the stock with a $33.00 price target.
Lyra Therapeutics (LYRA)
William Blair analyst Tim Lugo maintained a Buy rating on Lyra Therapeutics on August 6. The company’s shares closed last Friday at $13.50.
According to TipRanks.com, Lugo is a 5-star analyst with an average return of 16.2% and a 49.5% success rate. Lugo covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, BioMarin Pharmaceutical, and Adamas Pharmaceuticals.
Currently, the analyst consensus on Lyra Therapeutics is a Strong Buy with an average price target of $24.33, implying a 78.9% upside from current levels. In a report issued on August 5, Jefferies also reiterated a Buy rating on the stock with a $24.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
